KCPG
EBS icon

Kavar Capital Partners Group’s Emergent Biosolutions EBS Stock Holding History

Kavar Capital Partners Group’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-25
Closed -$1K – 167
2015
Q4 		$1K Buy
25
+11
+79% +$384 ﹤0.01% 387
2015
Q3 		$0 Buy
+14
New +$461 ﹤0.01% 495

Other funds holding EBS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Kavar Capital Partners Group's EBS Position: Q1 2016 in Review

Kavar Capital Partners Group sold out of Emergent Biosolutions (EBS) in Q1 2016, closing a stake of 25 shares — an estimated $1K sold.

Kavar Capital Partners Group first reported a position in EBS in Q3 2015 and held it in 2 quarters. The position peaked at $1K in Q4 2015. 214 funds tracked by Wall St. Rank hold EBS as of Q1 2016.

  • Kavar Capital Partners Group reported no remaining Emergent Biosolutions position as of Q1 2016 after selling out during the quarter.
  • Kavar Capital Partners Group sold 25 Emergent Biosolutions shares in Q1 2016, an estimated $1K.
  • Kavar Capital Partners Group first reported a position in Emergent Biosolutions in Q3 2015 and held it in 2 quarters.
  • Kavar Capital Partners Group's Emergent Biosolutions position peaked at $1K in Q4 2015.
  • 214 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2016.

Based on Kavar Capital Partners Group's 13F filing for Q1 2016, filed 13 May 2019.